Triple-agonist (investigational)
An investigational metabolic peptide in clinical trials.
Early-phase trial results in weight management have generated significant interest, but it remains investigational. Long-term safety and efficacy data are still being collected.
Anything sold as "retatrutide" online is outside the trial setting and unregulated — purity and identity cannot be assumed. Within trials, effects are monitored.
Investigational — not approved or marketed as a medicine in Australia. Any online "supply" is not a lawful pathway.
No lawful consumer supply. Legitimate access is only through participation in an approved clinical trial.
No. It is investigational and not a marketed medicine. Products sold online under this name are unregulated and not a lawful supply pathway.
This entry is general information about Retatrutide, not a recommendation to use it. We don’t provide dosing, protocols or sourcing. Speak to a registered practitioner.
This is general education, not medical advice. Peptides.au does not sell, supply, recommend or promote any product or clinic. Always speak with a registered Australian health practitioner before making any health decision.